Featured Publications
Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy
Baker ML, Yamamoto Y, Perazella MA, Dizman N, Shirali AC, Hafez N, Weinstein J, Simonov M, Testani JM, Kluger HM, Cantley LG, Parikh CR, Wilson FP, Moledina DG. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. Journal For ImmunoTherapy Of Cancer 2022, 10: e004421. PMID: 35354588, PMCID: PMC8968986, DOI: 10.1136/jitc-2021-004421.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisAcute kidney injuryImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyICI therapyKidney injuryInhibitor therapyInterstitial nephritisTime-varying Cox proportional hazards modelsHigher peak serum creatinineSevere acute kidney injuryCancer typesCox proportional hazards modelAssociations of biopsyBaseline laboratory valuesObservational cohort studyPeak serum creatinineFavorable treatment responseProportional hazards modelAKI patientsTherapy initiationCohort studySerum creatinineUnivariable analysisImmune activation
2024
Biomarker Panels for Predicting Progression of Kidney Disease in Acute Kidney Injury Survivors.
Menez S, Kerr K, Cheng S, Hu D, Thiessen-Philbrook H, Moledina D, Mansour S, Go A, Ikizler T, Kaufman J, Kimmel P, Himmelfarb J, Coca S, Parikh C. Biomarker Panels for Predicting Progression of Kidney Disease in Acute Kidney Injury Survivors. Clinical Journal Of The American Society Of Nephrology 2024 PMID: 39671257, DOI: 10.2215/cjn.0000000622.Peer-Reviewed Original ResearchAcute kidney injurySoluble tumor necrosis factor receptor 1End-stage kidney diseaseChronic kidney diseaseKidney diseaseFollow-upPost-AKI careDevelopment of end-stage kidney diseaseKidney-specific outcomesYears of follow-upCombination of clinical variablesReceiver-operating characteristic curveTumor necrosis factor receptor 1Progression of kidney diseaseSequelae of acute kidney injuryAdverse kidney eventsAge of study participantsAcute kidney injury survivorsDiuretic useEGFR declineKidney disease riskKidney eventsAKI patientsKidney injuryPost-discharge follow-up